GlobeNewswire•May 30, 2019 LOS ANGELES, May 30, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it will be presenting at the 9th Annual LD Micro Invitational on Wednesday, June 5th at 11:40 a.m. PT at the Luxe Sunset Boulevard Hotel in Los Angeles. The conference will…
DetailsGlobeNewswire•June 3, 2019 VANCOUVER, British Columbia, June 03, 2019 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQX: WMLLF; SSE: WMLCL; Frankfurt: EJZN) announces that, further to its news releases dated December 4, 2018 and April 4, 2019, its wholly-owned subsidiary, Wealth Copper Ltd. (“Wealth Copper”) has entered into a…
DetailsGlobeNewswire•June 19, 2019 OXNARD, Calif. , June 19, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it is collaborating with Canopy Growth Corporation (WEED.TO) (CGC), (“Canopy”) to develop a new low-dose cannabidiol (CBD) oral thin film (OTF) using CURE’s patented CUREfilm™ technology for global distribution. This CUREfilm…
DetailsPR NewswireJuly 12, 2019 DENVER, July 12, 2019 /PRNewswire/ — Ur-Energy Inc. (NYSE American: URG; TSX: URE) (“Ur-Energy”) and Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels”) confirm that they are unaware of any decision by the White House with respect to the U.S. Department of Commerce (“DOC”) investigation into the effects of uranium…
DetailsPR Newswire•July 15, 2019 LAKEWOOD, CO, July 15, 2019 /PRNewswire/ – Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels” or the “Company”), the largest uranium producer in the U.S., is pleased to announce that our petition, filed jointly with Ur-Energy Inc. under Section 232 of the Trade Expansion Act of 1962, has been…
DetailsGlobeNewswire•July 16, 2019 OXNARD, Calif., July 16, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 15/666,057, which covers edible thin films with natural active ingredients located in both a powder coating and the film matrix for a bi-phasic release profile. “With…
DetailsGlobeNewswire•July 24, 2019 OXNARD, Calif., July 24, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 13/890,875. The new patent builds on one of CURE’s key technology differentiators – loading higher amounts of drug active on an oral thin film (OTF) using…
DetailsGlobeNewswire•August 7, 2019 OXNARD, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the addition of two directors to its Board, Dr. Lauren Chung, Ph.D. and Mrs. Anya Goldin. Dr. Chung has experience in healthcare investments and academic accomplishments in scientific fields and Goldin brings…
Details